Filgrastim biosimilar (NCPC GeneTech Biotechnology Development)

非格司亭生物类似药（华北制药金坦）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameFilgrastim biosimilar (NCPC GeneTech Biotechnology Development)
Drug Alias NamerhG-CSF - North China Pharmaceutical Corporation重组人粒细胞刺激因子（NCPC GeneTech Biotechnology Development）非格司亭生物仿制药（NCPC GeneTech Biotechnology Development）Recombinant human granulocyte macrophage colony stimulating factor (NCPC GeneTech Biotechnology Development)GeSysin
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionColony stimulating factor 3 receptor agonists
TargetsColony stimulating factor 3 receptor
Therapy Area/IndicationsNeutropenia
Global Approved IndicationsNeutropenia
Approved Indications in ChinaNeutropenia
Original Approved Country/TerritoryMainland China
Original Approved Date1999/01/01
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesNorth China Pharmaceutical Company Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNorth China Pharmaceutical Company Ltd
Inactive CompaniesN/A
Active IndicationsNeutropenia
Inactive IndicationsN/A

Other Information

ATC CodeL03AA02
Related LinksN/A